12
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T38436 | JAK-2/3-IN-1 | ||
JAK-2/3-IN-1 is a highly effective inhibitor targeting both JAK-2 and JAK-3 isoforms. It exhibits remarkable potency, with Ki values below 250 nM for both isoforms. | |||
T15607 | JAK3-IN-1 | Others | |
JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM). | |||
T9814 | JAK3/BTK-IN-1 | JAK , BTK | |
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inh... | |||
T6S1141 | Ganoderic acid A | Apoptosis , NF-κB , Endogenous Metabolite , Autophagy | |
1. Ganoderic acid A exhibits antitumor activity, mediated through its inhibitory effect on nuclear transcription factor-kappaB and activator protein-1. 2. Ganoderic acid A can induce proliferation inhibition, apoptosis a... | |||
T6S1966 | Curculigoside | Curculigoside A | Antioxidant , NF-κB , JAK , STAT |
1. Curculigoside (Curculigoside A) can prevent bone loss , improve osteogenesis and inhibit osteoclastogenesis of hAFSCs, suggesting its potential use to regulate hAFSC osteogenic differentiation for treating bone disord... | |||
T11703 | JAK-IN-1 | Others | |
JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. | |||
T79222 | JAK-IN-29 | JAK | |
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1]. | |||
T60895 | JAK-2/3-IN-3 | ||
JAK-2-/3-IN-3 (compound ST4j) can be used in lymph derived diseases and leukemia research. JAK-2-/3-IN-3 inhibits JAK2 autophosphorylation and induces apoptosis in a time- and dose-dependent manner. JAK-2-/3-IN-3 is a po... | |||
T82018 | JAK-IN-33 | JAK | |
JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1]. | |||
T38623 | Ifidancitinib | ATI-502,ATI-50002 | |
Ifidancitinib, a potent and selective inhibitor of JAK kinases 1/3, is utilized in the research of allergies, asthma, and autoimmune diseases. | |||
T61323 | JAK-2/3-IN-2 | ||
JAK-2/3-IN-2 (Compound 3h) is a potent dual inhibitor of JAK2 and JAK3. It exhibits inhibitory activity with IC50 values of 23.85 nM and 18.9 nM against JAK2 and JAK3, respectively [1]. | |||
T78207 | Lepzacitinib | JAK | |
Lepzacitinib, a Janus kinase inhibitor, specifically targets JAK 1/3. It demonstrates an anti-inflammatory effect and efficacy in inhibiting atopic dermatitis as well as other skin diseases [1]. |